Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsVancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announc ...

InMed Pharmaceuticals Conference Call Summary Company Overview - **Company Name**: InMed Pharmaceuticals - **Ticker Symbol**: INM (NasdaqCM) - **Industry**: Drug Development - **Focus**: Targeting CB1 and CB2 receptors for neurodegenerative diseases, particularly Alzheimer's disease [2][3] Key Drug Candidates - **INM-901**: - Targets neural inflammation in Alzheimer's disease - Orally bioavailable, disease-modifying therapeutic - Can cross the blood-brain barrier [2][3] - **INM-089**: - Focuses on dry age-related macular degeneration (AMD) - Aims to stop disease progression and potentially reverse damage [22][24] - **INM-755**: - Targets chronic severe itch in epidermolysis bullosa - Phase 2A studies showed meaningful improvement in itch scores [27][28] Alzheimer's Disease Insights - **Neuroinflammation**: - Emerging research indicates it may be a precursor to Alzheimer's, rather than a result [6][10] - INM-901 aims to modulate inflammation by targeting CB1 and CB2 receptors [7][8] - **Preclinical Results**: - INM-901 showed neuroprotective effects, reduced inflammation, and improved cognitive outcomes in animal models [9][20] - Significant reduction in pro-inflammatory markers observed [19][20] Dry AMD Insights - **Market Opportunity**: - Dry AMD has a larger patient population and high unmet medical need [22] - INM-089 demonstrated preservation of retinal function in preclinical studies [25][26] Financial Snapshot - **Cash Position**: Approximately $7 million as of December 31, sufficient to reach Q4 of the current year [31] - **Market Capitalization**: Around $4 million, considered low for the technology and team in place [31][32] Development Timeline - **INM-901**: - Targeting pre-IND meeting with the FDA in Q3 2026 - Clinical trials expected to begin in 2027 [32][33] - **INM-089**: - Similar timeline, potentially a quarter behind INM-901 [33] Intellectual Property - **Patent Portfolio**: - Broad patents covering the class of compounds and their modifications - Positioned for both in-house development and potential out-licensing opportunities [41][42] Strategic Initiatives - Focus on strategic partnerships and co-development opportunities to accelerate product development [34][33] Conclusion - InMed Pharmaceuticals is positioned with promising drug candidates targeting significant medical needs in neurodegenerative diseases and ocular conditions. The company is actively pursuing regulatory pathways and strategic partnerships to enhance its development capabilities and market presence [34][32]

Core Insights - InMed Pharmaceuticals is advancing its Alzheimer's disease program, particularly focusing on the INM-901 drug candidate, with plans to initiate a Phase 1 clinical trial in 2027 [1][3][10] INM-901 Program Outlook - INM-901 is a proprietary, orally bioavailable small molecule drug candidate that targets neuroinflammation in Alzheimer's disease by acting as a CB1/CB2 signaling agonist [3][4] - The company has generated preclinical evidence showing that INM-901 reduces inflammatory biomarkers and neurodegenerative markers, indicating its potential therapeutic effects [4][9] - The program aims to clarify its focus on neuroinflammation, which is believed to be a primary driver of Alzheimer's progression, rather than a secondary effect [4][5] Development Plans for 2026 - The company plans to conduct a pre-IND meeting with the FDA in Q3 2026 to discuss the INM-901 program, which is seen as a critical milestone [3][10] - Continued development of INM-089, a candidate for dry age-related macular degeneration, is also planned, with a pre-IND meeting targeted for Q4 2026 [6][10] - The company is executing IND-enabling pharmacology and toxicology studies, with a focus on advancing drug substance and product development [9][10] Scientific and Operational Progress - Significant progress has been made in understanding the anti-neuroinflammatory effects of INM-901, with data supporting its multifactorial mechanism of action [2][5] - Preclinical studies have shown improvements in cognitive function and neuronal regeneration, reinforcing the drug's potential efficacy [9][10] - The company is also working on optimizing drug formulation and scaling up manufacturing processes to support future studies [9][10]

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal legislation.As previously announced, H.R. 5371, the "Continuing Appropria ...

Core Viewpoint - InMed Pharmaceuticals reported its financial results for the second quarter of fiscal year 2026, highlighting progress in its drug development pipeline, particularly in neuroinflammation treatments for Alzheimer's disease and dry age-related macular degeneration [1][3]. Business Update - Pharmaceutical Development Programs - INM-901 is advancing as a potential treatment for Alzheimer's disease, focusing on modulating neuroinflammation. Recent pharmacokinetic studies in large animals showed robust bioavailability and no adverse effects, supporting its progression to human clinical trials [3][4]. - INM-089 is under investigation for treating dry age-related macular degeneration, with successful preclinical studies demonstrating significant improvements in disease models [5]. Financial Commentary - BayMedica's commercial business generated revenues of $0.8 million for the three months ending December 31, 2025, a 26% decrease from $1.1 million in the same period last year, primarily due to pending changes in U.S. legislation [6]. - Research and development expenses were $0.6 million for the quarter, down from $0.9 million year-over-year, attributed to reduced spending on external contractors and research supplies [7]. - General and administrative expenses were $1.6 million for the quarter, slightly down from $1.7 million in the previous year [8]. - As of December 31, 2025, the company had cash and short-term investments totaling $7.0 million, down from $11.1 million on June 30, 2025, with expectations to fund operations into the fourth quarter of calendar year 2026 [9]. Legislative Impact - The U.S. congressional legislation H.R. 5371, if enacted, could negatively impact BayMedica's commercial business by prohibiting certain aspects of its operations related to rare cannabinoids [10]. - BayMedica is exploring alternative options but has not set a timetable for decisions regarding its commercial business, which may include divesting or pivoting operations [11].

Financial Performance - Total sales for the three months ended December 31, 2025, were $820,188, a decrease of 26.2% compared to $1,111,707 for the same period in 2024[18]. - Gross profit for the six months ended December 31, 2025, was $587,353, down 38.4% from $954,307 in 2024[18]. - The net loss for the three months ended December 31, 2025, was $2,028,223, compared to a net loss of $2,575,024 for the same period in 2024[18]. - For the six months ended December 31, 2025, the net loss was approximately $3.8 million, compared to a net loss of $4.3 million for the same period in 2024, representing a decrease of about 11.5%[22]. - Net loss for the three months ended December 31, 2025, was $2,028,223, compared to a net loss of $2,575,024 for the same period in 2024, representing a 21.3% improvement[95]. - For the six months ended December 31, 2025, total sales were $1,940,309, down 18.3% from $2,376,345 in the same period of 2024[95]. - Research and development expenses for the three months ended December 31, 2025, were $630,636, a reduction of 29.6% from $895,176 in 2024[18]. - Research and development expenses for the six months ended December 31, 2025, were $1,212,248, a decrease of 24.1% compared to $1,595,321 in the same period of 2024[95]. Cash and Assets - Cash and cash equivalents decreased to $6,954,834 as of December 31, 2025, from $11,075,871 as of June 30, 2025[16]. - Cash and cash equivalents as of December 31, 2025, were $6,954,834, an increase from $5,583,039 as of June 30, 2025[95]. - Total assets decreased to $11,191,484 as of December 31, 2025, from $15,580,040 as of June 30, 2025[16]. - Total cash used in operating activities for the six months ended December 31, 2025, was approximately $3.98 million, compared to $4.33 million for the same period in 2024, indicating improved cash management[22]. - The company expects its cash and cash equivalents will be sufficient to fund operations into the fourth quarter of calendar 2026, depending on revenue realization from BayMedica[28]. Liabilities and Deficits - Total liabilities decreased to $1,603,820 as of December 31, 2025, from $2,145,545 as of June 30, 2025[16]. - The company reported an accumulated deficit of $120,993,014 as of December 31, 2025[16]. - As of December 31, 2025, the accumulated deficit reached approximately $121.0 million, reflecting ongoing financial challenges[27]. - The company has substantial doubt about its ability to continue as a going concern within one year from the issuance of the financial statements[30]. Funding and Capital - The company has raised capital primarily through the sale of common shares, with a private placement generating $1.03 million in 2024[27]. - The company plans to seek additional funding through equity financings, debt financings, or collaborations, but may face challenges in obtaining financing on acceptable terms[29]. - The Company completed a Private Placement on June 26, 2025, issuing 1,952,363 common shares at a price of $2.561 per share, resulting in gross proceeds of approximately $5.0 million[75]. - The Company issued 1,208,336 Common Shares for gross proceeds of approximately $6.2 million during the year ended June 30, 2025, after offsetting $0.4 million in related fees[80]. Inventory and Expenses - The company reported an inventory write-down of $70,000 during the six months ended December 31, 2025, indicating potential issues with inventory management[22]. - The Company recorded an inventory write-down of $70,000 due to net realizable value during the three and six months ended December 31, 2025, compared to no write-down in the same period of 2024[69]. - Total inventories as of December 31, 2025, amounted to $947,898, with a total inventory reserve of $278,737[68]. - The company incurred share-based compensation expenses of approximately $45,469 for the six months ended December 31, 2025, down from $52,123 in the same period of 2024[22]. - Total expenses from share-based payment transactions for the three months ended December 31, 2025, were $25,564, with $16,829 allocated to general and administrative expenses[87]. Customer Concentration - Customer concentration risk for the three months ended December 31, 2025, shows that Customer A accounts for 30% of revenues, while Customer B accounts for 22%[43]. - As of December 31, 2025, accounts receivable concentration risk indicates that Customer F represents 37% and Customer G represents 32% of total accounts receivable[43]. Other Agreements and Legal Matters - The company has entered into a technology license agreement with a third party, which includes annual royalty payments contingent on net sales of products made using the licensed process[103]. - The company is currently involved in arbitration proceedings regarding a technology license agreement, which could have a material adverse impact on its business and financial condition[107]. - The company has not recognized any liabilities related to indemnification obligations, believing the fair value of these obligations is minimal[102].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - WhiteFiber, Inc. (WYFI) is up 21% at $17.35 [3] - Rising Dragon Acquisition Corp. (RDAC) is up 21% at $12.63 [3] - Julong Holding Limited (JLHL) is up 13% at $3.45 [3] - Linkhome Holdings Inc. (LHAI) is up 11% at $12.50 [3] - A SPAC III Acquisition Corp. (ASPC) is up 9% at $13.09 [3] - Intuitive Machines, Inc. (LUNR) is up 7% at $11.61 [3] - Ascent Solar Technologies, Inc. (ASTI) is up 7% at $3.31 [3] - Bitmine Immersion Technologies, Inc. (BMNR) is up 6% at $30.39 [3] - Velo3D, Inc. (VELO) is up 5% at $12.10 [3] - Gain Therapeutics, Inc. (GANX) is up 4% at $2.36 [3] Premarket Losers - cbdMD, Inc. (YCBD) is down 17% at $1.60 [4] - Mega Fortune Company Limited (MGRT) is down 16% at $7.33 [4] - Cassava Sciences, Inc. (SAVA) is down 14% at $2.43 [4] - NIKE, Inc. (NKE) is down 10% at $59.01 [4] - InMed Pharmaceuticals Inc. (INM) is down 6% at $1.21 [4] - Datacentrex, Inc. (DTCX) is down 5% at $3.23 [4] - Abundia Global Impact Group Inc (AGIG) is down 5% at $1.50 [4] - PSQ Holdings, Inc. (PSQH) is down 5% at $1.00 [4] - Paranovus Entertainment Technology Ltd. (PAVS) is down 4% at $2.34 [4] - Worksport Ltd. (WKSP) is down 4% at $2.09 [4]

Group 1 - InMed Pharmaceuticals held its 2025 Annual General Meeting of Shareholders, chaired by CEO Eric Adams [1][2] - The meeting included a sworn declaration confirming that all materials were mailed to security holders as of October 22, 2025 [3]

Core Viewpoint - InMed Pharmaceuticals is facing potential negative impacts on its subsidiary BayMedica due to the recently signed H.R. 5371 Act, which may prohibit certain aspects of BayMedica's commercial business if enforced in its current form [3][5]. Group 1: Impact of the Act - The Act could materially affect BayMedica's inventory of rare, non-intoxicating cannabinoids, which may be prohibited under the new legislation set to take effect on November 12, 2026 [3][5]. - InMed is currently evaluating alternative supply chain options to ensure regulatory compliance for BayMedica [3][6]. - The company acknowledges uncertainty regarding whether the sections of the Act impacting BayMedica will ultimately be enforced or amended before the effective date [5]. Group 2: Commitment to Core Programs - Despite the potential challenges posed by the Act, InMed remains focused on its core pharmaceutical drug development programs, which are not affected by the new legislation [4]. - The company continues to advance its drug candidates, including INM-901 for Alzheimer's disease and INM-089 for age-related macular degeneration [4]. Group 3: Ongoing Operations - BayMedica is continuing its normal business operations while evaluating the potential impact of the Act, with no set timetable for concluding its evaluation or making definitive decisions on alternative options [6].

InMed Pharmaceuticals Conference Call Summary Company Overview - **Company Name**: InMed Pharmaceuticals (NasdaqCM: INM) - **Industry**: Pharmaceutical drug development - **Focus**: Proprietary small molecule drug candidates targeting CB1 and CB2 receptors [2][3] Key Drug Development Programs 1. **INM-901 for Alzheimer's Disease** - Target: Alzheimer's disease affecting up to 7.2 million Americans [5] - Preclinical data shows: - Statistically significant reduction in neuroinflammation [6] - Improvement in neuron growth and cognitive functions [7] - Ability to cross the blood-brain barrier [6] - Multiple mechanisms of action including neuroprotection and reduction of amyloid beta [8][10] - Long-term studies indicate improved behavior and cognition in animal models [11] 2. **INM-089 for Dry Age-Related Macular Degeneration (AMD)** - Target: Dry AMD affecting approximately 19.8 million Americans [16] - Mechanism: Preserves retinal function and heals damaged photoreceptor cells [17][18] - Delivery method: Injection into the eye [18] 3. **INM-755 for Epidermolysis Bullosa (EB)** - Focus: Cannabinol cream for chronic itch in EB patients [19] - Phase two clinical trial showed 66% of patients experienced clinically meaningful improvement in chronic itch [20] Financial Overview - **Cash Position**: $9.3 million as of September 30, providing approximately one year of runway [25] - **Market Capitalization**: Approximately $5.6 million [25] - **Shares Outstanding**: 4.2 million, fully diluted 6.7 million [25] Strategic Initiatives - Seeking partnerships for funding phase three trials, particularly for INM-755 [21] - Continuing to explore strategic partnerships to expedite drug development [22][23] - Focus on advancing INM-901 and INM-089 towards IND filings [26] Future Catalysts - Identifying strategic partners for drug development [30] - Presenting positive data at scientific conferences to attract interest [31] - Continued progress in preclinical studies for both INM-901 and INM-089 [32] Additional Insights - The company emphasizes the importance of addressing neuroinflammation in Alzheimer's and other diseases [12][28] - The leadership team is experienced in drug development, which is seen as a key strength [3][24] - The company maintains a clean balance sheet with no debt, allowing for focused investment in R&D [25]